Document Type

Article

Publication Title

Pediatric Medicine

Abstract

Background and Objective: Alport syndrome is a hereditary disorder of type IV collagen that commonly presents in childhood with persistent hematuria and carries a lifelong risk of progressive kidney disease and extrarenal complications. Despite advances in genetic diagnostics, important gaps remain in early risk stratification, variant interpretation, and recognition of expanding phenotypes. This narrative review aims to synthesize current evidence on the genetic architecture, clinical spectrum, and management of pediatric Alport syndrome, with a focus on early diagnosis and disease-modifying interventions.

Methods: A targeted literature search was conducted using PubMed/MEDLINE to identify English-language human studies published between January 2000 and September 2025. Search terms included “Alport syndrome”, “COL4A3”, “COL4A4”, “COL4A5”, “type IV collagen”, and related clinical and genetic keywords, combined using Boolean operators. Relevant cohort studies, clinical trials, systematic reviews, and consensus guidelines were prioritized, and reference lists of key articles were manually reviewed. Findings were synthesized using a narrative approach.

Key Content and Findings: Alport syndrome demonstrates substantial genetic and phenotypic heterogeneity, with X-linked (XL), autosomal recessive (AR), autosomal dominant (AD), and digenic forms contributing to a broader disease spectrum than previously recognized. Genotype-phenotype correlations, particularly variant type and gene involvement, are critical determinants of disease severity and progression. Early initiation of renin-angiotensin-aldosterone system (RAAS) blockade, especially in genetically confirmed cases, has been shown to delay progression to kidney failure. Advances in next-generation sequencing have improved diagnostic yield but introduced challenges in variant interpretation, including variants of uncertain significance (VUS). Emerging phenotypes, such as cystic kidney disease, further expand the clinical spectrum and have implications for differential diagnosis and genetic counseling.

Conclusions: A genetics-first approach is central to the management of pediatric Alport syndrome, enabling early diagnosis, risk stratification, and timely initiation of therapy. Integration of genetic findings with clinical features is essential for individualized care. Recognition of evolving phenotypes and ongoing advances in targeted therapies highlight the need for pediatric-specific research to optimize outcomes and refine precision medicine strategies.

DOI

10.21037/pm-26-0027

Publication Date

8-30-2026

Keywords

Alport syndrome, pediatrics, type IV collagen, genetic testing, chronic kidney disease (CKD)

ISSN

2617-5428

Download

Share

COinS